Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

18 déc. 2025 07h00 HE | Source: Nutriband Inc.

Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction

Fentanyl designation Response
03 sept. 2025 16h01 HE | Source: Nutriband Inc.

Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000

warrant conversion
18 août 2025 09h00 HE | Source: Nutriband Inc.

Nutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025

Presentation announcement
18 juil. 2025 09h15 HE | Source: Nutriband Inc.

Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval

Dividend dates reminder
02 juil. 2025 08h05 HE | Source: Nutriband Inc.

Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval

Stock dividend
18 juin 2025 07h00 HE | Source: Nutriband Inc.

Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-up for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

Commercial Scale up complete for AVERSA
09 juin 2025 07h30 HE | Source: Nutriband Inc.

Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology

New Patent issuance
03 juin 2025 08h00 HE | Source: Nutriband Inc.

Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference

noble conference announcement
02 juin 2025 08h00 HE | Source: Nutriband Inc.

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl

Q1 results
30 avr. 2025 07h30 HE | Source: Nutriband Inc.

Nutriband CEO Publishes Letter to Shareholders

2025 Letter to Shareholders